{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:02:06Z","timestamp":1792098126206,"version":"4.4.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1681\/asn.2014070697","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T00:25:43Z","timestamp":1423787143000},"page":"2248-2258","source":"Crossref","is-referenced-by-count":197,"title":["Corticosteroids in IgA Nephropathy"],"prefix":"10.1681","volume":"26","author":[{"given":"Vladimir","family":"Tesar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phan","family":"Troyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubha","family":"Bellur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobien C.","family":"Verhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Terence","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Feehally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian S.D.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cattran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20230208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.V82199","article-title":"Predicting renal outcome in IgA nephropathy.","volume":"8","author":"Radford","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"R2-22-20230208","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semnephrol.2007.10.001","article-title":"Natural history of primary IgA nephropathy.","volume":"28","author":"Berthoux","year":"2008","journal-title":"Semin Nephrol"},{"key":"R3-22-20230208","doi-asserted-by":"crossref","first-page":"e91756","DOI":"10.1371\/journal.pone.0091756","article-title":"Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan.","volume":"9","author":"Moriyama","year":"2014","journal-title":"PLoS One"},{"key":"R4-22-20230208","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/ki.2012.280","article-title":"The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2014Application to the individual patient.","volume":"82","author":"Radhakrishnan","year":"2012","journal-title":"Kidney Int"},{"key":"R5-22-20230208","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial.","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R6-22-20230208","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"R7-22-20230208","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification.","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"R8-22-20230208","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: A randomised controlled trial.","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"R9-22-20230208","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R10-22-20230208","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial.","volume":"53","author":"Lv","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R11-22-20230208","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy.","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R12-22-20230208","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10157-012-0744-x","article-title":"The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy.","volume":"17","author":"Hirano","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"R13-22-20230208","first-page":"180691","article-title":"Corticosteroids in patients with IgA nephropathy and severe chronic renal damage.","volume":"2012","author":"Pozzi","year":"2012","journal-title":"Case Rep Nephrol"},{"key":"R14-22-20230208","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1159\/000064080","article-title":"Can immunosuppressive therapy be useful in IgA nephropathy when the \u2018Point of No Return\u2019 has already been exceeded?","volume":"92","author":"Pozzi","year":"2002","journal-title":"Nephron"},{"key":"R15-22-20230208","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R16-22-20230208","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10157-007-0497-0","article-title":"Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.","volume":"11","author":"Mitsuiki","year":"2007","journal-title":"Clin Exp Nephrol"},{"key":"R17-22-20230208","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10157-011-0415-3","article-title":"Steroids and azathioprine in the treatment of IgA nephropathy.","volume":"15","author":"Stangou","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"R18-22-20230208","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5301\/jn.5000110","article-title":"IgA nephropathy with severe chronic renal failure: A randomized controlled trial of corticosteroids and azathioprine.","volume":"26","author":"Pozzi","year":"2013","journal-title":"J Nephrol"},{"key":"R19-22-20230208","first-page":"284","article-title":"Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: Rationale and study protocol.","volume":"21","author":"Eitner","year":"2008","journal-title":"J Nephrol"},{"key":"R20-22-20230208","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/ndt\/gft016","article-title":"Is a legacy effect possible in IgA nephropathy?","volume":"28","author":"Coppo","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R21-22-20230208","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10157-012-0644-0","article-title":"Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy.","volume":"16","author":"Tatematsu","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"R22-22-20230208","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility.","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"R23-22-20230208","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0272-6386(00)70326-X","article-title":"Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy.","volume":"35","author":"Shoji","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R24-22-20230208","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/ajkd.2002.31399","article-title":"Regression of IgA nephropathy: A repeat biopsy study.","volume":"39","author":"Hotta","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R25-22-20230208","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research.","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"R26-22-20230208","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semnephrol.2004.01.006","article-title":"Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.","volume":"24","author":"Tumlin","year":"2004","journal-title":"Semin Nephrol"},{"key":"R27-22-20230208","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R28-22-20230208","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1373\/clinchem.2008.122218","article-title":"Estimating equations for glomerular filtration rate in children: Laboratory considerations.","volume":"55","author":"Miller","year":"2009","journal-title":"Clin Chem"},{"key":"R29-22-20230208","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"R30-22-20230208","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/00004872-200210000-00019","article-title":"Distribution of 24-h ambulatory blood pressure in children: Normalized reference values and role of body dimensions.","volume":"20","author":"W\u00fchl","year":"2002","journal-title":"J Hypertens"},{"key":"R31-22-20230208","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/pds.969","article-title":"Principles for modeling propensity scores in medical research: A systematic literature review.","volume":"13","author":"Weitzen","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201509000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:26:55Z","timestamp":1786130815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201509000-00022"}},"subtitle":["A Retrospective Analysis from the VALIGA Study"],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014070697","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725354649.793513949","asserted-by":"object"}]},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}